An interventional study of hippotherapy sessions in Parkinson Disease, sponsored by Central Hospital Saint Quentin. Recruiting at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2024-07-17.
Sponsored by Central Hospital Saint Quentin · Not applicable, Interventional, and Supportive care
Among 428 studies in Parkinson Disease with a site in France — 63 open to participants now, 76 under way, 4 of them phase 3. Parkinson Disease · France.
Among the 428 studies in Parkinson Disease with a site in France, this one is the 219th largest by planned enrollment of the 328 interventional ones that give a count, is one of 21 that started in 2023, is one of 179 with no phase, reaches primary completion later than 8 of the 75 other live ones, and was the 336th registered.
4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →63 of the 428 studies in Parkinson Disease with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
University Hospital Tuebingen · Sites in France, Germany, Italy and 4 more countries
Hospices Civils de Lyon · Sites in France
University Hospital, Grenoble · Sites in France
University Hospital, Toulouse · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 63 take children under 18; 189 take healthy volunteers.
This study: 75 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
428 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 67 · Phase 3 52 · Phase 4 17
First in 1990; this study’s year is marked. 21 started in 2023.
This study's planned enrollment of 36 is close to the median of 40 across 3,353 interventional studies indexed under Parkinson Disease.
Median enrollment 64 across the 328 interventional studies, 90 across the 98 observational. Of the 318 that completed or were terminated, 60 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
121 of 428 have an industry lead sponsor. The 10 most frequent:
Central Hospital Saint Quentin is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Central Hospital Saint Quentin has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
21 of the studies in Parkinson Disease with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06080659Rennes University HospitalNetwork-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity | 2026-11 |
| NCT04179695University Hospital, LilleEvaluation of a New Communication Aid Tool to Favor Global Patient Centered Care | 2026-12 |
| NCT07083089Cilcare SASEarly Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR) | 2026-12 |
| NCT06401395DIAMPARKClinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING) | 2027-01-01 |
| NCT06576713University Hospital, Strasbourg, FranceCombined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism | 2027-01-01 |
Among the 428 studies in Parkinson Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There is no cure for Parkinson's disease, resulting in an interest for research in this domain. Non pharmacological measures remain essential, specifically physical activity. Hippotherapy is a nonconventional method which uses the horse in addition to standard care. The goal being to improve or maintain the gains of the person through cognitive, sensorial and motor stimulation, with the aim of improving quality of life and maintaining independence. With this in mind, the researchers propose to evaluate quality of life as the main criterion, using the PDQ8 scale validated for this disease. The researchers hope results will lead to the coverage of the costs of non-conventional therapies such as hippotherapy by social security services.
Parkinson's disease is a degenerative disorder with a prevalence of 2.50 patients per 1,000 people in 2015. Prevalence and incidence increase progressively with age up to the age of 80; more than half of patients are over 75.
There are two main types of Parkinson's disease in the elderly:
The therapeutic management of Parkinson's disease in the elderly must be assessed on a case-by-case basis. The efficacy/tolerance ratio of dopaminergic treatments must be taken into account.
In Alzheimer's disease (AD), it has been shown that aerobic exercise can delay cognitive decline. With this in mind, the researchers would like to propose a new and original approach using equitherapy in elderly Parkinson's patients.
The aim of this therapy will be to improve patients' quality of life, particularly in terms of well-being, maintain and encourage their autonomy and promote social interaction.
Equitherapy is an unconventional therapy which uses the horse as a complement to the treatment. For the EQUIDIA study, the researchers have suggested using the PDQ-8 score, validated for this condition, to evaluate quality of life as well as well-being and cognitive capacity for a group of Parkinson's patients over the age of 75 following 6 therapy sessions.Their Parkinson's diagnosis is to be confirmed through morphological and phase contrast MRI. The sessions will take place at the same interval of time following the administration of any dopaminergic medication. Progress will be recorded by the hippotherapy therapist using an evaluation developed by a horse-riding instructor. Sessions will be evaluated using inertia measurement devices to analyze quality of movement and the effect of specific activites with the horse.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will benefit from the hippotherapy sessions in additional to continuing to receive traditional care ,To evaluate any differences between the initial visit and the evaluation following 6 weeks in PDQ8 scores, which contain 8 items given a score between 0 (never) and 4 (always)
Other: hippotherapy sessions
Patients benefit from the hippotherapy sessions in additional to continuing to receive traditional care.
Assessing quality of life in Parkinson's disease by PDQ8 questionnaires
changes from baseline in PDQ8 scores, which contain 8 items given a score between 0 (never) and 4 (always) maximum control; range, 0 to 32.
Time frame: 06 weeks
Assessing Parkinson's disease Motor disorders
Motor disorders assessed by Mbientlab devices .
Time frame: 06 weeks
Assessing Parkinson's disease severity of the non-motor symptoms
The severity of the non-motor symptoms of Parkinson's disease assessed by the score on the non-motor symptoms assesment scale for Parkinson's Disease. This is a 30-question questionnaire. For each question, a severity score ranging from 0 (none) to 3 (severe) and a frequency score ranging from 1 (rarely) to 4 (very frequent) are to be indicated.
Time frame: 06 weeks
Assessing Parkinson's disease Postural and walking disorders
Postural and walking disorders assessed by the Gait and Balance Scale (GABS) 33 (maximum control; range, 0 to 95). changes from baseline in severity motor signs of Parkinson's disease,assessed by the motor score of the MDS UPDRS scale.
Time frame: 06 weeks
MRI in diagnosis differential in Parkinson's disease
The usefulness of flow MRI in diagnosis differential in Parkinson's disease
Time frame: day 0
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jul 2024, 12 months after the start.
Of 1,291 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 12 months is below that.
Counting every sponsor, half of 1,367 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital Saint Quentin